BEIJING - China's leading medical device developer, Mindray Medical International, reprised its role as one of the region's most adept navigators of the shifting currents of global demand in the healthcare sector as it posted a double-digit rise in net earnings for the third quarter despite the worldwide financial maelstrom
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Coartem Baby to be rolled out in eight African countries in the autumn.
Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.
Public Company Edition: A breakthrough designation, data and deals prompted big follow-on public offerings in late June and early July, including $402.5m for Cidara, $250.8m for Kymera and $230m for Dyne. Also, Revolution Medicines accessed up to $2bn from Royalty Pharma.
